Globex Acquires Bald Hill Antimony Deposit, New Brunswick
February 16, 2021 09:00 ET
|
Globex Mining Enterprises Inc.
ROUYN-NORANDA, Quebec, Feb. 16, 2021 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz,...
Cavitation Technologies, Inc. Announces an Agreement with Partnership International, Inc.
February 16, 2021 09:00 ET
|
Cavitation Technologies, Inc
Chatsworth, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Cavitation Technologies, Inc. (OTCQB: CVAT) (BERLIN: WTC) announces an Agreement with Partnership International, Inc. (“PI”) --...
Routemaster Capital Appoints Wouter Witvoet, Founder of Secfi, as CEO
February 16, 2021 07:00 ET
|
Routemaster Capital Inc.
TORONTO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. (the “Company” or “Routemaster”) (NEO: DEFI, GR: RMJR) is pleased to announce it has appointed Wouter Witvoet as Chief Executive...
Basilea meldet für 2020 starke Finanzergebnisse und deutliche Fortschritte in ihrer klinischen Onkologie-Pipeline
February 16, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Zweistelliges Wachstum der direkt realisierten Umsatzbeiträge durch Cresemba und ZevteraBetriebsverlust um mehr als 50 % auf CHF 8.2 Mio. verringertUm 15% verbesserter Cashflow aus operativer...
Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
February 16, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Double-digit growth in Cresemba and Zevtera non-deferred revenue contributionsOperating loss reduced by over 50% to CHF 8.2 millionImproved operating cash flow by 15%, CHF 167 million year-end cash...
Basilea kündigt Veräusserung ihres chinesischen F&E-Tochterunternehmens an PHT International an
February 15, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 15. Februar 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie eine Vereinbarung über die Veräusserung ihres chinesischen F&E-Tochterunternehmens Basilea Pharmaceutica...
Basilea announces divestment of its Chinese R&D subsidiary to PHT International
February 15, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, February 15, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D)...
Routemaster Capital Completes Acquisition of 20% Interest in Valour Structured Products, a Leading Exchange Traded Product Company Focused on Digital Assets
February 12, 2021 07:00 ET
|
Routemaster Capital Inc.
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Routemaster Capital Inc. (the “Company” or “Routemaster”) (NEO: DEFI GR: RMJR) is pleased to announce that it has closed the transaction to acquire 20% of...
Basilea präsentiert auf ASCO GU Symposium Dosisfindungs-Ergebnisse für Derazantinib/PD-L1-Checkpoint-Inhibitor-Kombination aus FIDES-02-Studie für Patienten mit soliden Tumoren
February 12, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, 12. Februar 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass auf dem Symposium für urogenitale Krebserkrankungen der American Society of Clinical Oncology (ASCO GU 2021)...
Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium
February 12, 2021 01:15 ET
|
Basilea Pharmaceutica AG
Basel, Switzerland, February 12, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that data on the safety, tolerability and preliminary efficacy of the fibroblast growth factor...